A statement released earlier today by RBC Capital about Seattle Genetics (NASDAQ:SGEN) bumps the target price to $62.00
- Updated: October 9, 2016
Yesterday Seattle Genetics (NASDAQ:SGEN) traded 1.56% higher at $55.18. The company’s 50-day moving average is $51.03 and its 200-day moving average is $42.76. The last closing price is up 29.06% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Volume of trade was down over the average, with 623,669 shares of SGEN changing hands under the typical 763,412
Stating a potential upside of 0.12%, RBC Capital upped the target price of Seattle Genetics (NASDAQ:SGEN) to $62.00
Seattle Genetics has with a one year low of $26.02 and a one year high of $57.23 and has a market capitalization of $0.
General Company Details For Seattle Genetics (NASDAQ:SGEN)
Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company's pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.